34.07 USD
↗ 0.05 (0.15%)AT CLOSE (11:59 AM EDT)
Roivant Sciences Ltd. Common Shares
ROIVNASDAQ • USD
34.07
↘ 0.01 (0.01%)
POST MARKET (AS OF 05:53 PM EDT)
Post Market
AS OF 05:53 PM EDT
34.07
↘ 0.01 (0.01%)
Market: CLOSED
Roivant Sciences Ltd. Common Shares (ROIV) trades at $34.07 per share. Technicals currently rate "Strong Buy" while our fundamental analysis reads "Neutral". Notable factors include a robust Altman Z-Score, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Jun 26, 2026.
Open?$34.06
High?$34.45
Low?$33.72
Prev. Close?$34.02
Volume?12.4M
Avg. Volume?6.9M
VWAP?$34.07
Rel. Volume?1.81x
Bid / Ask
Bid?$32.06 × 100
Ask?$36.75 × 100
Spread?$4.69
Midpoint?$34.41
Valuation & Ratios
Market Cap?24.5B
Shares Out?719.3M
Float?371.0M
Float %?51.8%
P/E Ratio?N/A
P/B Ratio?5.41
EPS?-$0.42
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Employees
721
Market Cap
24.5B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2021-10-01
Address
7TH FLOOR, 50 BROADWAY
LONDON, SW1H 0DB
Phone: 441-295-5950
LONDON, SW1H 0DB
Phone: 441-295-5950
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?23
Z-Score?100
Momentum?50
Short Sent.?39
Piotroski F-Score?3/9Weak
Altman Z-Score?35.93Safe
Confidence?60%Moderate
Short InterestHigh
Short % of Float?8.96%Elevated
Short Interest?33.2M
Days to Cover?7.5
Free Float371.0M
Avg Daily Volume4.4M
Settlement Date2026-06-15
Financial Health
Current Ratio?18.37Strong
Quick Ratio?18.37Strong
Cash Ratio?5.05Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score58/100
P/E?N/A▾
P/B?5.41FAIR▾
Peers100
S&P34
P/S?2,966.77HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-18.0CHEAP▾
S&P97
EV/Sales?2,794.95HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?-6.6%WEAK▾
S&P10
ROA?-5.3%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-758558000
Enterprise Value?$23.1B
Fundamentals ratios updated end of day